The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice
Abstract
Although anti-CD20 immunotherapy effectively treats human lymphoma and autoimmune disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally unknown. To address this, anti-mouse CD20 mAbs were used in a mouse model in which the extent and kinetics of tissue B cell depletion could be assessed in vivo. CD20 mAb treatment depleted most mature B cells within 2 days, with 95–98% of B cells in the bone marrow, blood, spleen, lymph nodes, and gut-associated lymphoid tissues depleted by day 7, including marginal zone and follicular B cells. The few spleen B cells remaining after CD20 mAb treatment included pre-B, immature, transitional, and some B1 B cells that expressed CD20 at low levels. By contrast, peritoneal cavity B cells expressed normal CD20 densities and were coated with CD20 mAb, but only 30–43% of B1 cells and 43–78% of B2 cells were depleted by day 7. Spleen B cells adoptively transferred into the peritoneal cavity were similarly resistant to mAb-induced depletion, while transferred B cells that had migrated to the spleen were depleted. However, peritoneal B1 and B2 cells were effectively depleted in mAb-treated wild-type and C3-deficient mice by thioglycolate-induced monocyte migration into this otherwise privileged niche. Inflammation-elicited effector cells did not promote peritoneal cavity B cell depletion in FcR-deficient mice treated with CD20 mAb. Thus, the majority of CD20+ cells and B cell subsets within lymphoid tissues and the peritoneum could be depleted efficiently in vivo through Fc-dependent, but C-independent pathways during anti-CD20 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., & Carroll, M. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11490 · Cited by 503
Cited by
Yanaba, K., Bouaziz, J.-D., Haas, K. M., Poe, J. C., Fujimoto, M., & Tedder, T. F. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.017 · Cited by 1,238
Self-citationRegulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression
Matsushita, T., Yanaba, K., Bouaziz, J.-D., Fujimoto, M., & Tedder, T. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36030 · Cited by 913
Self-citationThe importance of natural IgM: scavenger, protector and regulator
Ehrenstein, M. R., & Notley, C. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2849 · Cited by 635
Zouggari, Y., Ait-Oufella, H., Bonnin, P., Simon, T., Sage, A. P., Guérin, C., Vilar, J., Caligiuri, G., Tsiantoulas, D., Laurans, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3284 · Cited by 559
Self-citationMechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Innate and Adaptive Immunity Cooperate Flexibly to Maintain Host-Microbiota Mutualism
Slack, E., Hapfelmeier, S., Stecher, B., Velykoredko, Y., Stoel, M., Lawson, M. A. E., Geuking, M. B., Beutler, B., Tedder, T. F., Hardt, W.-D., et al. (2009) · Science · doi:10.1126/science.1172747 · Cited by 503
Self-citationB cell depletion reduces the development of atherosclerosis in mice
Ait-Oufella, H., Herbin, O., Bouaziz, J.-D., Binder, C. J., Uyttenhove, C., Laurans, L., Taleb, S., Van Vré, E., Esposito, B., Vilar, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100155 · Cited by 469
Self-citationTreatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Hu, C.-Y., Rodriguez-Pinto, D., Du, W., Ahuja, A., Henegariu, O., Wong, F. S., Shlomchik, M. J., & Wen, L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32405 · Cited by 426
Regulatory B cells as inhibitors of immune responses and inflammation
Bouaziz, J., Yanaba, K., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00661.x · Cited by 425
Self-citationDiLillo, D. J., Hamaguchi, Y., Ueda, Y., Yang, K., Uchida, J., Haas, K. M., Kelsoe, G., & Tedder, T. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.361 · Cited by 385
Self-citationMurine Models of Systemic Lupus Erythematosus
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y., & Morel, L. (2011) · BioMed Research International · doi:10.1155/2011/271694 · Cited by 378
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 359
Self-citationBeers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
B‐lymphocyte contributions to human autoimmune disease
Yanaba, K., Bouaziz, J., Matsushita, T., Magro, C. M., St.Clair, E. W., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326
Self-citationTherapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice
Bouaziz, J.-D., Yanaba, K., Venturi, G. M., Wang, Y., Tisch, R. M., Poe, J. C., & Tedder, T. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709205105 · Cited by 314
Self-citationKyaw, T., Tay, C., Khan, A., Dumouchel, V., Cao, A., To, K., Kehry, M., Dunn, R., Agrotis, A., Tipping, P., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000033 · Cited by 311
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2017) · Kelley and Firestein's Textbook of Rheumatology · doi:10.1016/b978-0-323-31696-5.00069-3 · Cited by 278
Adaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Moore, G. L., Chen, H., Karki, S., & Lazar, G. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11158 · Cited by 266
Srinivasan, M., Flynn, R., Price, A., Ranger, A., Browning, J. L., Taylor, P. A., Ritz, J., Antin, J. H., Murphy, W. J., Luznik, L., et al. (2012) · Blood · doi:10.1182/blood-2011-07-364414 · Cited by 260
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
Impact of B‐cell‐targeted therapies on cardiovascular disease
Porsch, F., & Binder, C. J. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311996 · Cited by 29
Metadata
- Authors
- Hamaguchi, Y., Uchida, J., Cain, D. W., Venturi, G. M., Poe, J. C., Haas, K. M., & Tedder, T. F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-01
- Volume
- 174
- Issue
- 7
- Pages
- 4389-4399
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1633176708
- Cited by
- 212
- References
- 4
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.